EFFICACY OF IXEKIZUMAB IMPROVING SF-36 SCORES IN BIOLOGIC DMARD-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)

被引：0
|
作者：
Strand, V. [1 ]
Gottlieb, A. B. [2 ]
Kvien, T. K. [3 ]
Naegeli, A. [4 ]
Lin, C-Y. [4 ]
Benichou, O. [4 ]
Birt, J. [4 ]
机构：
[1] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA
[2] New York Med Coll, Valhalla, NY 10595 USA
[3] Diakonhjemmet Hosp, Oslo, Norway
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.2331
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0793
引用
收藏
页码：1334 / 1335
页数：2
相关论文
共 50 条
  • [31] Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
    Laura C. Coates
    Philip Mease
    Andris Kronbergs
    Cameron Helt
    David Sandoval
    So Young Park
    Bernard Combe
    Peter Nash
    Atul Deodhar
    Clinical Rheumatology, 2022, 41 : 3261 - 3261
  • [32] APREMILAST MONOTHERAPY AS THE FIRST SYSTEMIC TREATMENT IN DMARD-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 3-YEAR TREATMENT RESULTS
    Wells, A. F.
    Edwards, C. J.
    Kivitz, A. J.
    Bird, P.
    Nguyen, D.
    Shah, K.
    Teng, L.
    Aelion, J. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 342 - 342
  • [33] Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)
    Kameda, Hideto
    Hagimori, Kohei
    Morisaki, Yoji
    Holzkaemper, Thorsten
    Konomi, Ayako
    Dobashi, Hiroaki
    RHEUMATOLOGY AND THERAPY, 2023, 10 (06) : 1683 - 1703
  • [34] Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)
    Hideto Kameda
    Kohei Hagimori
    Yoji Morisaki
    Thorsten Holzkämper
    Ayako Konomi
    Hiroaki Dobashi
    Rheumatology and Therapy, 2023, 10 : 1683 - 1703
  • [35] Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naive Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
    Smolen, Josef S.
    Sebba, Anthony
    Ruderman, Eric M.
    Schulze-Koops, Hendrik
    Sapin, Christophe
    Gellett, Amanda M.
    Sprabery, Aubrey Trevelin
    Li, Lingnan
    de la Torre, Inmaculada
    Gallo, Gaia
    Liu-Leage, Soyi
    Pillai, Sreekumar
    Reis, Paulo
    Nash, Peter
    RHEUMATOLOGY AND THERAPY, 2020, 7 (04) : 1021 - 1035
  • [36] IXEKIZUMAB IMPROVES NAIL AND SKIN PSORIASIS THROUGH 52 WEEKS OF TREATMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO RANDOMIZED, DOUBLE-BLIND, PHASE 3, CLINICAL TRIALS (SPIRIT-P1 AND SPIRIT-P2)
    Merola, Joseph F.
    Kishimoto, Mitsumasha
    Adams, David
    Park, So Young
    Thaci, Diamant
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 16 - 16
  • [37] BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD- NAIVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE-REFERENCE STUDY BE OPTIMAL
    Mcinnes, I.
    Mease, P. J.
    Tanaka, Y.
    Behrens, F.
    Gossec, L.
    Husni, M. E.
    Kristensen, L. E.
    Warren, R. B.
    Ink, B.
    Bajracharya, R.
    Coarse, J.
    Eells, J.
    Gottlieb, A. B.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1133 - 1134
  • [38] IXEKIZUMAB MAKES VERY LOW DISEASE ACTIVITY AND REMISSION WITH PSORIATIC ARTHRITIS DISEASE ACTIVITY SCORE POSSIBLE IN ACTIVE PSORIATIC ARTHRITIS PATIENTS FOR UP TO 1 YEAR: SPIRIT-P1 AND SPIRIT-P2 TRIALS
    Coates, L. C.
    Husni, M. E.
    Lespessailles, E.
    Kerr, L.
    Gallo, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 375 - 375
  • [39] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P2)
    Gratacos-Masmitja, J.
    Turkiewicz, A.
    Dokoupilova, E.
    Gellett, A. M.
    Sprabery, T.
    Geneus, V. J.
    Constantin, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1154 - 1154
  • [40] An analysis of fatigue in patients with psoriatic disease utilizing SF-36 vitality scores: Results through week 24 in phase 3 trials of guselkumab in patients with psoriasis and psoriatic arthritis
    Merola, Joseph F.
    Liu, Yi-Hsuan
    Yang, Ya-Wen
    Miller, Megan
    Shawi, May
    Chan, Daphne
    Khattri, Saakshi
    Savage, Laura
    Boehncke, Wolf-Henning
    Han, Chenglong
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB137 - AB137
12345